THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND LIM...

by Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori
Published 2014-08-01

THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LI...

by Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori
Published 2014-08-01

THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LI...

by Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori
Published 2012-01-01

THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LI...

by Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori
Published 2012-04-01

Prognostic Assessment in Patients with Indolent B-Cell Lymphomas

by Luca Arcaini, Sara Rattotti, Manuel Gotti, Stefano Luminari
Published 2012-01-01

Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy

by Luca Arcaini, Michele Merli, Stefano Volpetti, Sara Rattotti, Manuel Gotti, Francesco Zaja
Published 2012-01-01

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers

by Manuel Gotti, Irene Defrancesco, Mario D’Angelo, Sabrina Basso, Sabrina Basso, Luca Crotto, Alfredo Marinelli, Alfredo Marinelli, Cristina Maccalli, Vincenzo Iaconianni
Published 2020-10-01